Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1
'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.'
Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin.
Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters.
Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities.
About amycretin
Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss.
About the phase 1b/2a subcutaneous amycretin trial
The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1
About the phase 1 oral amycretin trial
The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2
About obesity
Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7
The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
Contacts for further information
References
© 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025
View original content to download multimedia: https://www.prnewswire.com/news-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet-302487500.html
SOURCE NOVO NORDISK INC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support
Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings, and promote healthy weight loss management using vegan-friendly ingredients. nixol New York City, June 21, 2025 (GLOBE NEWSWIRE) --Nixol, a plant-powered metabolic support supplement, is now available to individuals across the United Kingdom. Designed to help individuals struggling with weight control and sluggish metabolism, Nixol Capsules offer a science-informed approach to supporting natural fat-burning processes and curbing unnecessary cravings—without extreme diets or synthetic additives. With more UK residents focusing on sustainable wellness, Nixol enters the market at a time when natural health solutions are in growing demand. These once-daily vegan capsules aim to provide convenient support for those on their journey toward a more energized and balanced lifestyle. Visit Official Website Addressing a Modern Wellness Challenge In today's fast-paced world, many people face common roadblocks to maintaining a healthy weight loss—slowed metabolism, irregular cravings, fatigue, and a lack of time to commit to complicated regimens. Nixol was developed with these challenges in mind. Its formula blends carefully selected ingredients believed to support metabolic efficiency and digestive health, all in an easy-to-take format that fits seamlessly into daily routines. Unlike solutions that rely on synthetic stimulants or temporary fads, Nixol takes a gentler, more sustainable route. It aims to support the body's own natural processes over time, helping individuals feel more in control of their eating habits, energy levels, and overall wellness goals. What Makes Nixol Different? Many products make bold promises—but Nixol's philosophy centers around realistic, natural progress. Here's how Nixol stands out: ✅ Vegan-Friendly Capsules: Free from gelatin, dairy, soy, and gluten. ✅ Non-GMO Ingredients: Manufactured with quality standards in mind. ✅ Once-Daily Dosage: Simplifies wellness routines with zero guesswork. ✅ No Harsh Stimulants: Gentle on the system while supporting energy. Rather than offering instant results or dramatic weight fluctuations, Nixol is built to be a long-term companion in a person's journey toward better health. Visit Official Website To get More InformationThe Power Behind the Nixol Formula Each serving of Nixol contains a thoughtfully selected blend of natural ingredients—each with potential benefits tied to metabolism, digestion, or appetite support. Key Ingredients Include: Apple Cider Vinegar Extract – 100 mg: Traditionally used for its potential to support digestion and appetite regulation. It's a popular natural aid for those trying to manage portion sizes and sugar cravings. Guarana Extract – 100 mg: A natural source of caffeine, guarana may help promote energy and alertness without the crash. It also contributes to thermogenic processes that can aid fat metabolism. Inulin Powder from Jerusalem Artichoke – 100 mg: A prebiotic fiber that nourishes beneficial gut bacteria. Inulin may support smoother digestion and better nutrient absorption. L-Glutamine – 50 mg: An amino acid that supports gut lining health and may play a role in reducing sugar cravings and supporting energy levels. L-Leucine – 50 mg: Known to assist in muscle maintenance during calorie restriction, leucine helps support lean body mass and recovery. Zinc – 14 mg (140% DV): Essential for hormone regulation, immune health, and metabolic processes. Zinc also plays a role in appetite and insulin sensitivity. Chromium – 40 mcg (100% DV): Linked to blood sugar control and reduced carbohydrate cravings. Chromium may assist in balancing energy and reducing spikes that lead to fatigue. These ingredients work together to offer synergistic support—helping users feel fuller for longer, more energized, and better equipped to make mindful eating Is Nixol For? Nixol is suitable for adult men and women who are: Looking for natural weight management support Struggling with low energy or poor digestion Interested in non-GMO and vegan-friendly supplements Seeking a gentle alternative to extreme diet pills Focused on long-term wellness over short-term fads Whether someone is starting a new fitness journey or simply wants to support their metabolism as they age, Nixol is designed to fit any lifestyle without requiring major lifestyle changes. Visit Nixol Official Website To Read More.. Trusted Manufacturing and Clean Label Promise All Nixol capsules are made in GMP-certified facilities to ensure safety and consistency. The company proudly avoids artificial fillers, synthetic preservatives, or questionable ingredients. The clean-label transparency ensures users know exactly what they're putting in their bodies—supporting trust and confidence in daily use. How to Use Nixol For Weight Loss Management Taking Nixol is as simple as adding one capsule to your morning routine. There's no need for timing it around meals or pairing it with complicated diet programs. For best results, the product is intended to be taken consistently over time while maintaining a generally healthy lifestyle. Hydration, light physical activity, and sleep hygiene can further enhance the benefits of any wellness supplement—including Nixol. The Bigger Picture: Supporting Confidence and Balance While weight management is often a numbers game in the media, Nixol approaches it differently. The goal is not to chase unrealistic ideals but to support real people in feeling better—physically and mentally. That might mean feeling confident in your own skin, having enough energy to enjoy time with loved ones, or simply ending the day with a calm digestive system. Nixol believes wellness should be achievable, empowering, and natural—and that's exactly the experience it aims to deliver. visit the official website here A Final Word In a crowded supplement market, Nixol offers something refreshingly straightforward: a natural tool to support better metabolic balance, digestion, and daily energy—all in one clean capsule. Its arrival in the UK opens up new possibilities for individuals seeking a simpler way to support their health without harsh chemicals or hype. As awareness grows around the importance of gut health, metabolism, and daily consistency, Nixol is positioned to become a trusted companion for thousands pursuing better wellness—one day at a time. Attachment nixol CONTACT: Media Contact: Nixol Health & Wellness Email: support@ Website: Phone: +44 (0)800 123 4567
Yahoo
an hour ago
- Yahoo
LSU picks search committee members to find its next president
LSU's Memorial Tower on Monday, March 20, 2023, on Tower Drive in Baton Rouge. (Matthew Perschall for Louisiana Illuminator) A search committee has been assembled to find LSU's next president. LSU is searching for a replacement for William Tate, who led both its Baton Rouge flagship campus and the LSU System that also includes medical schools in New Orleans and Shreveport, a New Orleans dental school and satellite institutions in Shreveport, Alexandria and Eunice. Tate departed Baton Rouge to become the leader of Rutgers University in New Jersey. Earlier this year, two board members confirmed to the Illuminator there is ongoing discussion over whether LSU will hire a system president and a separate chancellor for the its main campus. The school's news release announcing search committee members did not indicate whether there would be a separate search for a chancellor. LSU combined the two roles in 2012. Matt Lee, the dean of LSU's College of Agriculture, is serving as interim president. LSU Board of Supervisors chairman Scott Ballard announced the following list of individuals have been appointed to the 2025 LSU Presidential Search Committee, including himself as a member: Lee Mallett, LSU Board of Supervisors vice chairman Valencia Sarpy Jones, LSU Board of Supervisors past chair Rémy Voisin Starns, LSU Board of Supervisors past chair James Williams, LSU Board of Supervisors past chair John Carmouche, LSU Board of Supervisors Blaise Zuschlag, LSU Board of Supervisors Ben Bordelon, Bollinger Shipyards president and CEO Clarence Cazalot, LSU Foundation Board of Directors Paul Coreil, LSU Alexandria chancellor Greg Feirn, LCMC Health CEO E.J. Kuiper, Franciscan Missionaries of Our Lady Health System president & CEO Pete November, Ochsner Health CEO Roger Odgen, LSU Foundation Board of Directors Emily Otken, LSU Health Sciences Center Shreveport student, former LSU Board of Supervisors student member Kenneth Schafer, LSU Boyd professor and Ball Family distinguished professor Ryan Theriot, Former LSU baseball player Daniel Tirone, LSU A&M Faculty Senate president, associate professor Bill Windham, Shreveport-Bossier businessman Ballard told the Illuminator recently the board he predicts would work over the next six months or so to conduct a nationwide search for Tate's replacement. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Yahoo
an hour ago
- Yahoo
Meyer signs executive order shielding patients and providers of gender-affirming care
A newly signed executive order makes information on gender-affirming care more secure. Executive Order 11 was signed on June 10 in Rehoboth Beach. The order protects patients and providers from being forced to hand over information about gender-affirming care given in Delaware in most civil and criminal investigations and professional disciplinary actions. Medical records, data and billing information are included in the executive order. The executive order defines gender-affirming care as "any medically necessary healthcare or treatment consistent with current clinical standards of care prescribed by a licensed healthcare provider for the treatment of a condition related to the individual's gender identity and that is legal under Delaware law." The order forbids state agencies from supplying information on patients and providers of gender-affirming care in a civil or criminal investigation that is solely initiated on people providing, receiving, inquiring about, or responding to an inquiry regarding gender-affirming care or people traveling to Delaware to receive it. It also protects from out-of-state subpoenas. There are exceptions, like if there is a final and non-appealable court order or if required by federal or state law. The order also does not allow any medical boards in the state to bar or discipline providers of gender-affirming care on that lone basis. 'You can never erase us': Delaware bill to ban transgender care stalls, climate remains The order is designed to secure providers and patients from "hostile laws" in states that restrict gender-affirming care, a release from the governor's office said. 'Across the country, people are being punished for seeking or providing gender-affirming care,' said Gov. Matt Meyer in a statement on June 20. 'In Delaware, we cherish privacy, dignity and the right to make personal medical decisions. Everyone deserves the freedom to access healthcare rooted in science and compassion.' These restrictions are not unheard of. Delaware neighbors New Jersey and Maryland have very similar protections on the books. Shane Brennan covers Wilmington and other Delaware issues. Reach out with ideas, tips or feedback at slbrennan@ This article originally appeared on Delaware News Journal: DE executive order shields gender-affirming care patients, providers
